While it is well established that acute allergic urticaria is caused by degranulation of skin mast cells occurring after allergen/IgE-dependent cross-linking of high affinity IgE receptors (FcepsilonRI), the pathophysiologic mechanisms operative in chronic urticaria (CU) are less well understood. Some evidence points to the existence of histamine-releasing activity in the serum of CU patients which possibly acts via triggering of FcepsilonRI. In this study, we aimed to better characterize this anti-FcepsilonRIalpha reactivity of CU patients using affinity-purified, IgE-depleted IgG fractions of such individuals (CU-IgG). Using immobilized, recombinant soluble FcepsilonRIalpha as a a reaction target for Western blot studies, we found that 12/32 (37%) CU-IgG serum samples exhibited IgG autoreactivity against FcepsilonRI-alpha. These findings were confirmed by experiments demonstrating that immunoblot-reactive, but not immunoblot-nonreactive, CU-IgG preparations precipitated the FcepsilonRIalpha from FcepsilonRI-alphagamma-transfected cells. No antiFcepsilonRIalpha reactivity was observed in IgG fractions from atopic dermatitis (AD) patients (0/15) or healthy control individuals (CO:0/15). As opposed to the selective occurrence of IgG anti-Fc epsilon RI alpha autoantibodies in CU patients, IgG anti-IgE antibodies were detected in all groups investigated (CU: 69%; AD: 73%; CO: 26%). While both types of autoantibodies can exhibit histamine-releasing properties, not all of the autoantibodies proved to be functional in vitro. Our results indicate that the occurrence of IgG anti-FcepsilonRIalpha reactivity defines an autoimmune-mediated subentity of CU and […] 
Introduction
While it is well established that acute allergic urticaria is caused by degranulation of skin mast cells occurring after allergen/IgE-dependent cross-linking of high affinity IgE receptors (FceRI), the pathophysiologic mechanisms operative in chronic urticaria (CU) are less well understood. Some evidence points to the existence of histamine-releasing activity in the serum of CU patients which possibly acts via triggering of FcERI. In this study, we aimed to better characterize this anti-FcERIa reactivity of CU patients using affinity-purified, IgE-depleted IgG fractions of such individuals (CU-IgG). Using immobilized, recombinant soluble FcERIa as a reaction target for Western blot studies, we found that 12/32 (37%) CU-IgG serum samples exhibited IgG autoreactivity against FcERIa. These findings were confirmed by experiments demonstrating that immunoblot-reactive, but not immunoblot-nonreactive, CU-IgG preparations precipitated the FcERIa from FcERlay-transfected cells. No anti-FcERIx reactivity was observed in IgG fractions from atopic dermatitis (AD) patients (0/15) or healthy control individuals (CO: 0/15). As opposed to the selective occurrence of IgG anti-FcERIa autoantibodies in CU patients, IgG anti-IgE antibodies were detected in all groups investigated (CU: 69%; AD: 73%; CO: 26%). While both types of autoantibodies can exhibit histamine-releasing properties, not all of the autoantibodies proved to be functional in vitro. Our results indicate that the occurrence of IgG anti-FcERIa reactivity defines an autoimmune-mediated subentity of CU and provide a basis for the development of new diagnostic procedures and, perhaps, therapeutic strategies for this disease. (J. Clin. Invest. 1995. 96:2606-2612.) Key words: autoimmunity * IgE receptors * histamine release * mast cell degranulation * pseudoallergic reaction the eruption of transitory, itchy skin swellings which recur for weeks to years. Several conditions such as bacterial or fungal infections, psychological factors, neoplasms, and intolerance to certain food additives ( 1, 2) have been found in connection with CU symptoms and, thus, were implicated as etiopathogenetic factors. However, in a given patient, the tedious and laborious search for such conditions is usually not revealing and, even if successful and appropriately dealt with, not necessarily followed by the resolution of symptoms (1) .
Since urticaria is the consequence of vasoactive mediator release from skin mast cells (MC) (3) , intensive research has focused on the nature of histamine-releasing factors in CU. These studies accumulated evidence for the presence of MCactivating factors within the immunoglobulin (Ig) and/or nonimmunoglobulin (e.g., substance P and lipid-derived mediators) fraction of CU serum (2) . Classical Ig-mediated type I allergic reactions, i.e., allergen-induced cross-linking of IgE bound to its high affinity receptor (FcsRI) on skin MC (4, 5), are apparently not a common cause for the observed Ig-mediated histamine-releasing activity in CU since allergen-specific IgE can only rarely be identified and total IgE levels are usually normal in CU sera. Evidence for the pathogenetic importance of Ig isotypes other than IgE came from the observation that severe CU episodes can be ameliorated or even abolished after IgG adsorbance by plasmapheresis (6) . In fact, serum IgG antiIgE autoantibodies with MC-activating properties have been described in CU (7, 8) . Further evidence for a role of IgG autoantibodies in CU came from a recent study demonstrating histamine-releasing capacity of serum IgG isolates that could be blocked by soluble FceRIa chain (9) . Therefore, it was reasoned that FceRI can be a target structure recognized by IgG autoantibodies (9) . The experimental conditions chosen were not able to determine whether the observed FceRI-mediated MC degranulation was due to (a) in vivo formed IgG/anti-IgE autoantibody complexes (10) which may copurify with the IgG fraction, and/or (b) IgE-independent FcsRIa-specific IgG autoantibodies. To distinguish between these two possibilities, we investigated the antigen and epitope specificity of histaminereleasing autoantibodies in IgG fractions devoid of IgG/antiIgE complexes.
Methods
Patients and controls. 30 patients with CU, defined as recurrent wheals lasting < 24 h and occurring at least twice a week for over 2 mo, were recruited (2, 11 ). Patients with clinical evidence of urticarial vasculitis or physical urticaria were excluded. None of the patients were taking steroids or immunosuppressive drugs at the time of venipuncture. In addition, sera from 15 patients suffering from atopic dermatitis (AD) (12) were collected and sera from 15 Membrane-bound first-step antibodies were detected with either rabbit anti-human IgG (1:50,000) or rabbit anti-human IgE horseradish peroxidase conjugates (1:30,000). Membranes were incubated with ECL developing solution (Amersham International) and exposed to Kodak X-Omat S films. For the detection of autoantibodies with anti-IgE properties the following procedure was used: 200-400 ng/lane NP-conjugated BSA (BSA-NP) ( 17) were electrophoresed and blotted onto nitrocellulose membranes that were blocked with 5% dry milk/0.05% Tween 20/PBS before exposure to cIgE (10 gg/ml). The subsequent detection of membrane-bound IgG anti-IgE reactivity was performed as described above.
Immunoprecipitation. CHOa>y cells were solubilized in 1% NP-40
Tris-lysis buffer as described ( 18 ) . Before Histamine release. Histamine release assays were performed with basophil-enriched peripheral blood cells from two unrelated healthy volunteers. Removal of in vivo bound IgE from basophils was performed after dextran sedimentation as described (19) . Where indicated, basophils were reconstituted with cIgE (10 Ag/ml, 30 min, 4°C). Basophil- 
Results
Protein G isolates from serum of CU patients react with recombinant FcsRla. In a first set of experiments we aimed to gain biochemical evidence for the occurrence of anti-FceRIa immunoreactivity in CU sera. Our test system uses recombinant FcsRIa protein that has been expressed in baculovirus-infected insect cells as a truncated non-fusion protein lacking the transmembrane/intracytoplasmic domain. Westeni blot experiments revealed that the soluble FcsRIa is recognized by the FcERIa chain-specific mAb 19-1 as a single protein band of 30-35 kD and, to a lesser extent, as a dimer of -65 kD ( Fig. 1 A, left panel) that disappears under reducing conditions (data not shown). The availability of this recombinant material as immunoblotted reaction target for serum antibodies enabled us to investigate large numbers of serum samples for the presence of the postulated anti-FcsRIla immunoreactivity. Fig. 1 A depicts a representative immunoblot experiment showing that the protein G-binding fraction of a selected CU serum contains FceRIa-binding activity that can be detected with anti-human IgG Abs. The antigenic specificity of the phenomenon was demonstrated by the inhibition of the binding of FcsRIa-specific moieties by incubation of CU-IgG fractions with soluble aprotein before the reaction with the immunoblotted material ( Fig. 1 A) Fig. 3 A, (Fig. 3 B) . A virtually identical inhibitory effect on autoantibody-binding was observed when the FceRlay-transfected cells had been preincubated with cIgE (Fig. 3 B) . These findings strongly suggest that the anti-FceRIa autoreactivity present in CU sera is directed against IgE-binding epitopes and/or epitopes closely related to the IgE-binding site of FcsRIa. Surprisingly, high concentrations (200 Mig/ml) of cIgE were needed to completely prevent IgG autoantibody-binding to the transfectants (Fig. 3 B) ment). For control purposes, the binding of cIgE to BSA-NP was detected with an anti-IgE reagent (Fig. 4) . BSA-NP in the absence of IgE anti-NP was used to demonstrate the anti-IgE specificity of the observed serum IgG-binding (Fig. 4) . The comparison of anti-FcsRIa reactivity (Fig. 5 A) with anti-IgE reactivity (Fig. 5 B) revealed that both autoantibodies can, but do not necessarily, co-occur in CU sera.
In an extended patient study, we evaluated the prevalence
B IgG1
IgG2a -- anti-FceRIa reactivity is selectively present in CU patients and -within this disease entity-defines a subgroup of such patients. Anti-FcRIa and anti-IgE autoantibodies can induce histamine release from peripheral blood basophils. In an attempt to explore the biological role of autoantibodies against FcsRIa and/or IgE, CU-IgG specimens were analyzed for their capacity to release histamine from basophils of healthy donors. Exposure to anti-FceRIa autoantibody-positive IgG fractions revealed a substantial release of endogenous histamine in four out of eight cases (Fig. 6 , representative experiment, n = 3). The magnitude of this response was comparable with positive control stimulation. To investigate whether the lack of mediator release in approximately half of the CU patients with anti-FceRIa autoantibodies was due to the receptor blockade by in vivo bound IgE, IgE was eluted from basophils by lactic acid stripping before exposure to IgG fractions. Neither the removal of surface-bound IgE (data not shown) nor the reconstitution of the stripped cells with 10 pg/ml monomeric IgE changed the histamine-releasing capacity of anti-FcsRIa-containing specimens (Fig. 6 A) . Importantly, two of three anti-IgE-containing IgG fractions induced histamine release from basophils reconstituted with saturating doses of IgE (Fig. 6 A, representative experiment, three independent experiments). To investigate whether the failure of certain FceRIa-reactive IgG specimens to release histamine was due to low concentrations of autoantibodies present in these preparations, basophils were incubated with CU-IgG concentrations up to 5 mg/ml (dilution: 1:2). Fig. 6 B demonstrates that certain FceRIa-reactive CU-IgG specimens, even when applied in high concentrations, did not result in induction of histamine release, whereas others activated basophils irrespective of the concentration used. Importantly, FcsRIa-nonreactive IgG from CU or CO did not induce histamine release at any of the concentrations tested (Fig. 6 B) . Although not all of the anti-FceRIa and/or anti-IgE autoantibody-containing IgG fractions were able to release histamine from peripheral blood basophils (Fig.  6, A and B) , our data show that humoral autoimmune phenomena can be observed in the majority of CU patients and that, at least in a group of these patients, in vitro histamine release can be ascribed to the presence of autoantibodies.
Discussion
It is well known that serum of certain CU patients contains MC-activating properties as evidenced by its ability to elicit (a) localized urticarial skin reactions upon intradermal injection and (b) histamine release from basophils in vitro (8, 9 The lack of histamine-releasing capacity of certain FcsRIa-reactive and of all nonreactive IgG samples is not reverted by increasing the concentration of IgG. For this purpose, basophil-enriched leukocytes were stripped and exposed to 1:2, 1:5, 1:10, or 1:20 diluted CU-or CO-IgG. As a positive stimulation control, cells were treated with a mouse anti-IgE mAb; histamine release in the presence of incubation buffer alone (negative control) was always < 5% of total cellular histamine. Specific histamine release (%) is given on the ordinate (total cellular histamine minus spontaneous release = 100%).
we (this study) and others (8) were able to show that exposure of IgE-bound basophils to IgG anti-IgE antibody containing IgG fractions from CU patients can, but does not necessarily, induce histamine release from these cells. Although detected in the serum of most CU patients (reference 7 and this study), IgG anti-IgE autoantibodies have also been found in sera of patients suffering from atopic dermatitis (references 21-23 and this study) and, even, of healthy individuals (reference 24 and this study). In atopic individuals, the analysis of epitopes recognized by IgG anti-IgE autoantibodies revealed that these antibodies recognize mainly idiotypic Fab rather than framework IgE heavy chain determinants (25) . Therefore, they should have the potential to cross-link receptor-bound IgE rather than prevent Fc-IgE from binding to IgE receptors. Despite the presence of such autoantibodies, atopic patients-in contrast to CU patients-very rarely suffer from recurrent wheal-and-flare reactions in the absence of allergen. It is therefore quite unlikely that IgG anti-IgE autoantibodies play a major pathogenetic role in CU.
Recent evidence points to the possibility that IgG autoreactivity directed against the a chain of the high affinity receptor for IgE can elicit clinical symptoms in CU (9) . Although this study convincingly demonstrated IgG-mediated, FcERIa-dependent histamine release from basophils, the experimental strategies used did not exclude the possibility that in vivo formed, protein G-purified IgG/anti-IgE immune complexes were responsible for the observed phenomenon. Biochemical results obtained in our study definitively prove the existence of true IgG anti-FcsRla autoantibodies in CU sera by the demonstration that (a) anti-FceRIa-reactive serum antibodies were detected with anti-IgG but not anti-IgE reagents and that (b) strategies resulting in complete elimination of IgE from CUIgG samples (anti-IgE immunoabsorbance and selective heat denaturation of IgE) did not decrease IgG-mediated antiFcsRIa immunoreactivity. The evaluation of the prevalence of anti-FceRIa autoantibodies in CU and AD versus CO revealed that-in contrast to the anti-IgE reactivity-IgE-independent FceRIa-specific autoreactivity resides selectively in the IgG fraction of 37% of CU patients but was not detected in either the AD or the CO group. The preferential, if not selective, occurrence of IgG anti-FcsRIa autoantibodies in CU may not only constitute a discriminating disease marker but, further, may be of central pathophysiological relevance for the disease itself. To address this issue, we investigated the capacity of IgE-depleted anti-FcsRIa autoantibodies containing IgG fractions to release histamine from peripheral blood basophils. 50% of these CU-IgG preparations were able to elicit responses that were shown to be IgE-independent since a similar histamine release was observed when IgE-saturated and IgE-eluted basophils were used. The fact that not all of the anti-FceRIa-positive CU-IgG samples were able to release histamine in vitro suggests that factors other than the mere presence of the Abs, such as the affinity, epitope specificity, and/or IgG subtype composition of autoantibodies, may determine the outcome of the individual biological response. In particular, the subtype composition of autoantibodies is important for the quality and/or quantity of Putative complement fixing properties of these autoantibodies would explain why MC degranulation in CU is largely restricted to skin MC which-in contrast to lung MC-can be activated via the C5a receptor CD88 (27 Our data demonstrate that anti-FcERIa autoantibodies occur preferentially, or perhaps even selectively, in CU patients and that, at least in certain incidences, these autoantibodies can induce histamine releases. The observation that anti-FcsRIa antibodies apparently occur in a subset of CU patients only emphasizes the need for a reliable diagnostic screening system for this autoreactivity. The biochemical test system described in this study offers a routine diagnostic procedure for the detection of autoreactivity in CU sera and, therefore, allows the definition of an autoimmune-mediated subentity of this disease. Furthermore, these findings may form a basis for the development of new strategies for the treatment of CU. In this regard, the definition of non-IgE but autoantibody-binding peptides and their application in immunoaffinity-based selective elimination of FcsRIa-reactive autoantibodies may be a be a promising approach to the treatment of severe recalcitrant cases of CU.
